Next Article in Journal
Industrial Scale Manufacturing and Downstream Processing of PLGA-Based Nanomedicines Suitable for Fully Continuous Operation
Next Article in Special Issue
Therapeutic Vaccines Targeting Neoantigens to Induce T-Cell Immunity against Cancers
Previous Article in Journal
Dual-Drug Delivery via Zein In Situ Forming Implants Augmented with Titanium-Doped Bioactive Glass for Bone Regeneration: Preparation, In Vitro Characterization, and In Vivo Evaluation
Previous Article in Special Issue
Current Status of the Use of Multifunctional Enzymes as Anti-Cancer Drug Targets
Article

CHRNA5 Contributes to Hepatocellular Carcinoma Progression by Regulating YAP Activity

by 1,†, 1,†, 1, 1,2,* and 1,*
1
Department of General Surgery, Huashan Hospital, Fudan University, Shanghai 200040, China
2
Key Laboratory of Whole-Period Monitoring and Precise Intervention of Digestive Cancer, Shanghai Municipal Health Commission (SMHC), Institute of Fudan-Minhang Academic Health System, Minhang Hospital, Fudan University, Shanghai 200437, China
*
Authors to whom correspondence should be addressed.
These authors contributed equally to this work.
Academic Editors: Hassan Bousbaa and Patrick J. Sinko
Pharmaceutics 2022, 14(2), 275; https://doi.org/10.3390/pharmaceutics14020275
Received: 7 December 2021 / Revised: 15 January 2022 / Accepted: 20 January 2022 / Published: 25 January 2022
(This article belongs to the Special Issue Novel Anticancer Strategies (Volume II))
Hepatocellular carcinoma (HCC) is a major health concern worldwide. A better understanding of the mechanisms underlying the malignant phenotype is necessary for developing novel therapeutic strategies for HCC. Signaling pathways initiated by neurotransmitter receptors, such as α5-nicotinic acetylcholine receptor (CHRNA5), have been reported to be implicated in tumor progression. However, the functional mechanism of CHRNA5 in HCC remains unclear. In this study, we explored the role of CHRNA5 in HCC and found that CHRNA5 expression was increased in human HCC tissues and positively correlated with the T stage (p < 0.05) and AJCC phase (p < 0.05). The KM plotter database showed that the high expression level of CHRNA5 was strongly associated with worse survival in HCC patients. Both in vitro and in vivo assays showed that CHRNA5 regulates the proliferation ability of HCC by regulating YAP activity. In addition, CHRNA5 promotes the stemness of HCC by regulating stemness-associated genes, such as Nanog, Sox2 and OCT4. Cell migration and invasion assays demonstrated that CHRNA5 significantly enhanced the metastasis of HCC by regulating epithelial–mesenchymal transition (EMT)-associated genes. Furthermore, we found that CHRNA5 regulates the sensitivity of sorafenib in HCC. Our findings suggest that CHRNA5 plays a key role in the progression and drug resistance of HCC, and targeting CHRNA5 may be a strategy for the treatment of HCC. View Full-Text
Keywords: HCC; CHRNA5; metastasis; stemness property; sorafenib sensitivity HCC; CHRNA5; metastasis; stemness property; sorafenib sensitivity
Show Figures

Figure 1

MDPI and ACS Style

Fu, Y.; Ci, H.; Du, W.; Dong, Q.; Jia, H. CHRNA5 Contributes to Hepatocellular Carcinoma Progression by Regulating YAP Activity. Pharmaceutics 2022, 14, 275. https://doi.org/10.3390/pharmaceutics14020275

AMA Style

Fu Y, Ci H, Du W, Dong Q, Jia H. CHRNA5 Contributes to Hepatocellular Carcinoma Progression by Regulating YAP Activity. Pharmaceutics. 2022; 14(2):275. https://doi.org/10.3390/pharmaceutics14020275

Chicago/Turabian Style

Fu, Yan, Hongfei Ci, Wei Du, Qiongzhu Dong, and Huliang Jia. 2022. "CHRNA5 Contributes to Hepatocellular Carcinoma Progression by Regulating YAP Activity" Pharmaceutics 14, no. 2: 275. https://doi.org/10.3390/pharmaceutics14020275

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop